United Statescenterviewpartners.com
Centerview Partners LLC is an independent investment banking advisory firm founded in 2006 and headquartered in New York. The firm specializes in mergers and acquisitions (M&A), strategic advisory, restructurings, financing, and related services, having advised on transactions totaling approximately $4 trillion.
With around 500 professionals and offices in New York, London, Paris, Menlo Park, and San Francisco, Centerview serves clients across industries and geographies. It has notable experience in the chemicals sector, including transactions such as Solutia’s sale to Eastman Chemical and Westlake’s acquisition of Vinnolit. Recently, it acted as a financial advisor to Terns Pharmaceuticals in its acquisition by Merck.
None yet. When a new project in the record names Centerview Partners as owner, partner or investor, it shows here.
Precision platform targets pathogenic autoantibodies; MER511 Phase 1 shows strong reductions in thyroid‑stimulating antibodies; deal includes up to $2.875B in cash.
Adds BPL-003 (mebufotenin benzoate intranasal) and VLS-01 (DMT buccal); upfront $6.75/share plus up to $2.50/share CVR tied to development, regulatory and DEA-rescheduling milestones.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
$38/ADS cash + up to $9 CVR (max $47/sh); upfront equity ~$6.3B (CVR ~$1.5B). Lead OX2R agonist cleminorexton showed positive Phase 2a for narcolepsy and idiopathic hypersomnia. Close expected Q3
Acquirer to buy target biotech at $53/share (~$6.7B equity, ~$5.7B net). Lead oral allosteric BCR::ABL1 TKI showed week‑24 molecular responses in Phase1/2; expected Q2 2026.
